Skip to main content

Lynx Q1 Revenues and Losses Decrease

NEW YORK, May 15 - Lynx reported somewhat reduced first-quarter revenues today, amid an incremental increase in net losses.


The company, which has recently renewed contracts for its MPSS technology with the Institute for Systems Biology in Seattle and Millennium therapeutics, had revenues of $3.3 million for the quarter, compared to $5.0 million for the previous year's quarter. The company's losses totaled $4.0 million, compared to $3.8 million for the first quarter of last year.


Meanwhile, Lynx's R&D expenses decreased sharply year-over-year, to $3.6 million from $6.9 million for the first quarter of last year.


At the end of March, Lynx had $7.4 million in cash and cash equivalents, compared to $11.7 million at the end of December, 2002.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.